Sublingual administration testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex episodic androgen release hypogonadal men search physiological testosterone replacement therapy hypogonadal states inclusion complex HPBCD HPBCD solubility absorption HPBCD hypogonadal men mean age yr serum levels normal range separate experimental phases tablet sublingual SL T-HPBCD times days Acute pharmacodynamic changes baseline min administration first dose dose maximal concentration Cmax nmol/L min increase rapid decline normal range nmol/L half-life decline dihydrotestosterone DHT Cmax nmol/L min increase normal range nmol/L integrated value ratio T/DHT normal range increment androstenedione Cmax nmol/L min increase Cmax DHT androstenedione estrone normal range pmol/L Cmax baseline Serum LH levels significant change FSH days treatment cumulative increase basal DHT levels decline LH FSH levels change sex hormone-binding globulin levels Similar results dose capacity SL absorption certain dose T-HPBCD fluctuations SL administration T-HPBCD resemble endogenous episodic secretion HPBCD SL route sustained elevations DHT 